Ecpan Dsr contains Pantoprazole. Ecpan Dsr uses:

Ecpan Dsr is indicated where suppression of acid secretion is of therapeutic benefit. Ecpan Dsr Is registered in the foltawing indications:

  • Peptic ulcer diseases (PUD)
  • Gastro-esophageal reflux diseases
  • Treatment of ulcer resistant to M2 blocker
  • Treatment of ulcer induced by NSAIDs
  • Gl bleeding from stress or acid peptic diseases
  • Eradication of Helicobacter pylori
  • Zollinger-Ellison syndrome
  • Prophylaxis for acid aspiration syndrome during induction of anesthesia
Ads
Brand Name: Ecpan Dsr
Generic: Pantoprazole
Weight: 40.0 Mg
Type: Capsule
Therapeutic Class: Proton Pump Inhibitor
Manufacturer: MESMER PHARMACEUTICALS
Price: 107.1
Last Updated: 2020-11-22 18:15:00

Doses

Ecpan Dsr contains Pantoprazole 40.0 Mg. Ecpan Dsr doses

Tablet:

The usual recommended adult oral dose is 40 mg given once daily, preferably in the morning with or without food. The duration of therapy is ranging from 2-8 weeks.

  • Duodenal ulcers: Ecpan Dsr 40 mg tablet once daily for 2-4 weeks.
  • Gastric ulcer: Ecpan Dsr 40 mg tablet once daily for 4-8 weeks.
  • Reflux esophagitis: Ecpan Dsr 40 mg tablet once daily for 4-8 weeks.
  • Ulcers induced by NSAIDs: Ecpan Dsr 40 mg tablet once daily.
  • Maintenance therapy: Maintenance therapy should involve the lowest effective dose of the drug. Ecpan Dsr both 20 mg & 40 mg doses are safe and effective in maintaining patients with healed reflux esophagitis and PUD in remission.

IV Injection:

  • Duodenal ulcer and gastric ulcer: 40 mg once daily for 7-10 days
  • Gastroesophageal reflux disease associated with a history of erosive esophagitis: 40 mg once daily for 7-10 days
  • Prevention of rebleeding in peptic ulcer: IV 80 mg, followed by 8 mg/hour infusion for 72 hours
  • Prophylaxis of acid aspiration: 80 mg IV every 12 h for 24 h, followed by 40mg every 12 h
  • Long-term management of Zollinger-Ellison Syndrome and other pathological hypersecretory conditions: 80 mg IV every 12 hours, may increase to 80 mg every 8 hours if needed, may titrate to higher doses depending on acid output.

DIRECTION FOR USE OF IV INJECTION: Ecpan Dsr lyophilized powder and 0.9% Sodium Chloride Injection is for intravenous administration only and must not be given by any other route. Ecpan Dsr IV injection should be given as a slow intravenous injection. The solution for IV injection is obtained by adding 10 ml 0.9% Sodium Chloride Injection to the vial containing powder. After reconstitution the injection should be given slowly over a period of at least 2 to 5 minutes. Use only freshly prepared solution. The reconstituted solution may be stored at room temperature (up to 30° C) for a maximum 4 hours.

DIRECTION FOR USE OF IV INFUSION: Ecpan Dsr IV infusion should be given as an intravenous infusion over a period of approximately 15 minutes. Ecpan Dsr IV infusion should be reconstituted with 10 ml of 0.9% Sodium Chloride Injection and further diluted (admixed) with 0.9% Sodium Chloride Injection or 5% Dextrose or Lactated Ringer's Injection to a final volume of 100 ml. The reconstituted solution may be stored at room temperature (up to 30° C) for a maximum 4 hours prior to further dilution. The admixed solution may be stored at room temperature (up to 30° C) and must be used within 24 hours from the time of initial reconstitution.

Side Effects

No potentially life-threatening effects have been reported with Ecpan Dsr. Symptomatic adverse effects include headache and diarrhoea are two common reported adverse effects. Peripheral edema has been occasionally reported in female patients. Other side effects may include abdominal pain, dizziness, nausea, epigastric discomfort, flatulence, skin rash, pruritus etc.

Ads
Introduction

Ecpan Dsr is chemically a novel substituted benzimidazole derivative, which suppresses the final step in gastric acid production by forming a covalent bond to two sites of H+/K+ATPase enzyme system at the secretory surface of the gastric parietal cell. This leads to inhibition of both basal and stimulated gastric effect that persists longer than 24 hours.

Ecpan Dsr is quantitatively absorbed and its bioavailability does not change upon multiple dosing. Ecpan Dsr is extensively metabolized in the liver. Almost 80% of an oral dose is excreted as metabolites in urine; the remainder is found in feces.

Precaution

Patients should be cautioned that Ecpan Dsr tablet should not be split, crushed or chewed. The tablet should be swallowed whole, with or without food in the stomach. Concomitant administration of antacid does not affect the absorption of Ecpan Dsr.

Interaction

There is no interaction with concomitantly administered antacids. No dosage adjustment is needed with combination use of the following drugs: Theophylline, Caffeine, Diazepam, Digoxin, Ethanol, Metoprolol, Nifedipine or Warfarin.

Pregnancy Lactation use

There are no adequate or well-controlled studies in pregnant women. Ecpan Dsr should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

It is not known whether Ecpan Dsr is excreted in human breast milk. Ecpan Dsr should be used during lactation only if the potential benefit justifies the potential risk.

Contraindication

It is contraindicated in patients with known hypersensitivity to Ecpan Dsr.

Special Warning

 

Acute Overdose

There are no known symptoms of overdosage in humans. Since Ecpan Dsr is highly protein bound, it is not readily dialyzable. Apart from symptomatic and supportive management, no specific therapy is recommended.

Interaction with other Medicine

 

Storage Condition

Store in a cool, dry place and away from light. Keep out of the reach of children.

Ecpan Dsr Capsule price in India 107.1

Ads